Moderate

Differentiated thyroid cancer follow-up

thyroid Ca · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Long-term surveillance of papillary and follicular thyroid cancer after surgery, using thyroglobulin, neck ultrasound and risk-adapted TSH suppression. Most patients have excellent prognosis with dynamic risk stratification.

Red flags

  • Rising thyroglobulin trend
  • New suspicious cervical lymphadenopathy
  • Hoarseness or dysphagia (local recurrence)
  • Rapidly enlarging mass (anaplastic transformation)
  • Symptomatic distant metastases

Assessment

Differential diagnosis

  • Benign thyroid nodule
  • Medullary thyroid cancer
  • Anaplastic thyroid cancer
  • Thyroid lymphoma
  • Metastasis to thyroid

Investigations

  • Serum thyroglobulin and anti-thyroglobulin antibodies
  • Neck ultrasound for nodal/bed recurrence
  • TSH and free T4 to guide suppression
  • Stimulated thyroglobulin or diagnostic radioiodine scan in selected cases
  • Cross-sectional imaging for suspected distant disease

Management

  • Stratify initial risk (low/intermediate/high) using ATA criteria
  • Set TSH target by risk: suppressed <0.1 (high), 0.1-0.5 (intermediate), 0.5-2.0 mU/L (low-risk, excellent response)
  • Measure thyroglobulin on levothyroxine with antibody status at each review
  • Perform neck ultrasound periodically for structural recurrence
  • Reassess as dynamic response (excellent, indeterminate, biochemical, structural incomplete)
  • De-escalate TSH suppression once excellent response achieved
  • Investigate rising thyroglobulin or suspicious nodes with imaging and biopsy
  • Consider further surgery or radioiodine for structural recurrence
  • Use targeted kinase inhibitors for progressive radioiodine-refractory disease

Drugs & doses

Levothyroxine titrated to risk-based TSH target
Radioactive iodine (I-131) for remnant ablation/recurrence per protocol
Lenvatinib or sorafenib for radioiodine-refractory progressive disease
Selpercatinib/other targeted agents for actionable mutations

Disposition

Lifelong endocrine/oncology follow-up with multidisciplinary review; refer progressive or refractory disease for systemic targeted therapy.

Complications & pitfalls

  • Local/nodal recurrence
  • Distant metastasis (lung, bone)
  • Over-suppression causing atrial fibrillation/osteoporosis
  • Radioiodine-related sialadenitis
  • Radioiodine-refractory progression

Exam pearls

  • Thyroglobulin is the key tumour marker but is uninterpretable when antibodies are present
  • Dynamic risk restratification lets most low-risk patients relax TSH suppression over time
  • Neck ultrasound detects most recurrences, which are usually nodal
  • Balance suppression benefit against cardiac and skeletal harm, especially in the elderly

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.